According to a recent LinkedIn post from Forge Biologics, the company recently hosted a group of students for a summer program focused on hands-on scientific work across its operations. The post highlights activities spanning upstream and downstream processing, assay development, environmental monitoring, and AAV and plasmid-related work.
The content suggests Forge is investing in early-career talent development and exposing students to Good Manufacturing Practice and quality-focused workflows. For investors, this emphasis on workforce cultivation may indicate a strategy to build a deeper talent pipeline in advanced biologics manufacturing.
The post also underscores the breadth of Forge’s technical capabilities, from upstream and downstream science to vector production and plasmid support. This broad operational exposure may signal the company’s intent to maintain or expand integrated services in gene therapy manufacturing, which could be relevant for its competitive positioning in the CDMO and cell and gene therapy ecosystem.
While the post is framed in a celebratory and informal tone, the emphasis on training and laboratory experience implies ongoing investment in human capital and operational know-how. Such initiatives can support long-term scalability and quality, factors that are often critical to sustaining growth and attracting partnerships in the biomanufacturing sector.


